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Abstract
Purpose Primary immunodeficiency diseases (PIDDs) are a heterogenous group of disorders characterized by intrinsic impair-
ment in the immune system. Most patients with PIDD require life-long immunoglobulin G replacement therapy, which has been
shown to reduce the rate of infections and, related hospitalizations and reduce health-related quality of life (HRQOL). Here,
treatment satisfaction and HRQOL in patients with PIDD was evaluated upon switching from intravenous (IVIG) or subcuta-
neous immunoglobulins (SCIGs) to 20% SCIG (Hizentra®), and during long-term steady-state Hizentra® treatment.
Methods Analyses were based on two pivotal (switch) and four extension/follow-up (maintenance) Phase III studies of
Hizentra® conducted in Europe (EU), Japan (JP), and the United States (US). Two validated questionnaires were used: Life
Quality Index (LQI) for assessment of IgG-specific perceptions of HRQOL and Short Form 36 version 2 (SF-36v2).
Results In the EU and JP switch studies, there was significant andmeaningful improvement from Screening in LQI domain scores at
all time points, largely driven by patients switching from IVIG to SCIG. In the EU switch study, there were also significant increases
in mean SF-36v2 domain scores for Physical Function and General Health from Screening to Week 12. These improvements were
observed also at Week 24. Overall, LQI and SF-36v2 domain scores were generally sustained in the maintenance studies.
Conclusions These results showed that switching patients from IVIG to SCIG improves patient self-reported health status and
IgG-specific HRQOL perception. The maintenance studies generally showed no deterioration of this improved health status over
a long follow-up period.
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Introduction
Primary immunodeficiency diseases (PIDDs) consist of a het-
erogenous group of disorders in which there is an intrinsic
impairment in the body’s immune system [1, 2]. While up to
300 types of PIDD are recognized, common variable immu-
nodeficiency and X-linked agammaglobulinemia are two of
the most common [1, 2]. The true prevalence of PIDD is not
well established, but estimates suggest that PIDD affects 1 in
2000 children, 1 in 1200 individuals of any age, and 1 in 600
households in the United States (equivalent to 150,000–
360,000 patients) [3].
PIDD imposes a significant disease burden on patients,
including limitations in work, play, and normal physical ac-
tivity [4]. In comparison with healthy children and adults,
patients with PIDD experience measurably lower general
health with higher hospitalization rates and increased physi-
cal, school, and social activity limitation [5–7]. Further, pa-
tients with PIDD fare even worse than those with other chron-
ic conditions with respect to general health perceptions [8, 9].
Fortunately, effective treatment of PIDD is available and
associated with patient benefit. Most patients with PIDD
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require life-long immunoglobulin G (IgG) replacement thera-
py, which has been directly shown in longitudinal studies to
decrease not only the rate of life-threatening bacterial infec-
tions and related hospitalizations [10, 11], but also improve
health-related quality of life (HRQOL) [12].
Since IgG therapy can be administered either intravenously
(IVIG) or subcutaneously (SCIG) [13–16] and constitutes life-
long treatment, the choice of modality of administration can
have major implications for patient well-being over their life-
time [17]. Evidence suggests that the efficacy of IgG therapy
is similar whether it is administered as SCIG or IVIG [18, 19],
yet compared to IVIG, SCIG offers the benefits of more stable
serum IgG levels, increased patient flexibility due to self-
administration and flexible dosing schedules, and a lower rate
of systemic adverse events (AEs) [20, 21]. Furthermore, phar-
macokinetic modeling has previously shown that doses can be
administered at varying intervals (daily to biweekly) with little
impact on serum IgG levels [22, 23].
SCIG, which has been gaining significant favor as an ad-
ministration route [22, 23], is almost always administered in a
home setting. It has the potential to improve several important
aspects of HRQOL in patients with PIDD, including fewer
limitations with regard to work or other daily activities and
reduced impact of treatment on everyday life [21].
There are a variety of SCIG formulations available, includ-
ing those with IgG concentrations of 10%, 16%, or 20%, and a
recombinant human hyaluronidase-facilitated SCIg (fSCIg)
[18, 24, 25]. Hizentra® (IgPro20, CSL Behring, Bern,
Switzerland) was the first 20% liquid IgG product for subcu-
taneous administration [26]. The high IgG concentration in
Hizentra® allows for a small infusion volume and a short
infusion time, thereby further increasing flexibility of dosing
and potentially patient HRQOL [21, 27, 28].
Herein, we report results from a pooled analysis of
HRQOL results from two pivotal Phase 3 studies and four
follow-up/extension studies in patients with PIDD from
Europe (EU), the United States (US), and Japan (JP), upon
switching from IVIG or another SCIG to Hizentra® and dur-
ing long-term maintenance Hizentra® treatment.
Methods
Patients and Study Designs
This pooled analysis included HRQOL data from six prospec-
tive, open-label, multicenter, single-arm, Phase 3 studies of
efficacy and safety of Hizentra® in patients with PIDD: EU
pivotal (NCT00542997) [29] and extension (NCT00751621)
[15] studies; JP pivotal (NCT01199705) [30], follow-up
(NCT01458171), and extension (NCT01461018) studies;
US extension (NCT00719680) [15] study. HRQOL was not
assessed in the US pivotal study (NCT00419341) [28]. The
clinical study protocols, informed consent forms, and any oth-
er appropriate study-related documents were reviewed and
approved by an Independent Ethics Committee (IEC)/
Institutional Review Board (IRB) for the individual studies.
The pivotal studies were designed to evaluate a switch to
Hizentra® from IVIG or other SCIG (hereafter referred to as
Bswitch studies^), while the follow-up/extension studies were
designed to evaluate long-term continuation of Hizentra®
therapy (hereafter referred to as Bmaintenance studies^).
Patients in the EU switch study could switch from IVIG or
another SCIG to Hizentra®, whereas all patients in the US and
JP switch studies switched from IVIG to Hizentra®.
The study design and methods of all seven studies have
been previously reported [15, 26, 28, 30]. Inclusion criteria
for the switch studies included confirmed PIDD previously
treated with IVIG at 3–4 weekly intervals (JP switch study:
for at least three doses; US switch study: for at least 3 months),
the EU switch study included patients on IVIG or SCIG at
regular weekly intervals, both for at least 6 months. Patients
were aged 2–75 years in all switch studies (JP: aged≤ 75 years;
EU: aged 2–65 years [16–65 in UK]; US: aged 2–75 years).
Major exclusion criteria for the switch studies included
newly-diagnosed PIDD (i.e., not having received previous
IgG replacement therapy); serious bacterial infection (SBI)
at the time of screening or first infusion; malignancies of lym-
phoid cells such as lymphocytic leukemia, non-Hodgkin’s
lymphoma, and immunodeficiency with thymoma; a positive
result at screening for any of the following viral markers:
human immunodeficiency virus, hepatitis C virus, or hepatitis
B virus.
For the maintenance studies, inclusion criteria included
confirmed PIDD and participation in the preceding switch
study. Exclusion criteria for these studies included ongoing
SBIs at the time of first infusion, hypoalbuminemia, protein-
losing enteropathies, and any proteinuria.
Patients enrolled in the studies received weekly subcutane-
ous infusions of Hizentra®. Several infusions were performed
under supervision at the study site, the rest were administered
at home by the patient or patient’s caregiver.
Patient-Reported Outcomes
Two validated questionnaires were used: the Life Quality
Index (LQI) for assessment of IgG-specific perceptions of
HRQOL and the Short Form 36 version 2 (SF-36v2) [21]
for assessment of general health status (patient functioning
and wellbeing).
The LQI is an instrument specifically designed to evaluate
perceptions of HRQOL, among patients receiving IgG treat-
ment [31]. The LQI questionnaire consists of 15 treatment-
specific items developed to examine the impact of IgG treat-
ment on patients’ convenience, comfort, and independence, as
well as assessing the impact of treatment schedule flexibility,
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pleasantness of treatment setting, disruption of daily activities,
treatment-related time involvement, and cost burden. The LQI
is summarized into four domains: Treatment Interference,
Therapy-related Problems, Therapy Setting, and Treatment
Costs. The LQI domains are scored from 0 to 100, with higher
scores associated with better IgG treatment-specific HRQOL.
LQI was evaluated at the following time points (Fig. S1):
Screening, Week 12, Week 24, and Week 40 in the EU switch
study; Month 6, 12, 18, 24, 30, 36, 42, or Study End (defined
as the last available post-Screening observation for each pa-
tient) in the EU maintenance study; Screening, Week 12, and
Week 24 in the JP switch and JP maintenance studies; and
Week 1 and Week 60 in the US maintenance study.
The SF-36v2 is a generic tool that assesses health status
using 36 items across 8 domains: Physical Functioning, Role
Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health, as well as
an item on Reported Health Transition. Following standard
scoring of the SF-36v2, raw scores on each domain were
transformed to a 0 to 100 scale (higher scores representing
better health status), using the following formula:
actual rawscore − lowest possible rawscore
highest possible raw score−lowest possible raw score
 
 100
Normalizing the results to known US or UK populations
(i.e., using T-scores) was not performed, as the studies were
not specific to these countries. The SF-36v2 questionnaire was
administered at the same time points as the LQI, with the
exception of the US maintenance study (at Week 0, 24, 48,
72, and 96; Fig. S1).
Statistical Analysis
All analyses were conducted using SAS version 9.4 (SAS
Institute Inc., Cary, NC, US). Comparisons across time points
were made by fitting a linear mixed effect model on repeated
measurements, with compound symmetry as the covariance
structure and visit as the only explanatory variable.
Changes from Screening were estimated using least
squares (LS) means derived from this model and are, there-
fore, not identical with simple numerical differences between
means. Significance of change scores on the various domains
of the LQI and the SF-36v2 were not adjusted for multiplicity.
No substantive changes in the model results were seen with
other correlation structures tested.
In addition to statistical significance, the clinical meaning-
fulness of each of the changes in the switch studies was eval-
uated based on within-group Cohen effect sizes [32]. Effect
sizes in the range 0.2–0.5 were deemed at least minimally
meaningful, 0.5–0.8 moderately meaningful, and those above
0.8 highly meaningful [32].
The analysis populations for both LQI and SF-36v2 assess-
ments consisted of all patients in the HRQOL set (all enrolled
patients with screening and ≥ 1 follow-up HRQOL assess-
ments; EU switch and maintenance studies, US maintenance
study) or the full analysis set (FAS; all patients treated with
Hizentra® during the efficacy period; JP switch and mainte-
nance studies). Questions from LQI and SF-36v2 were ana-
lyzed individually and by domain.
Results
Patient Disposition
Out of a total of 125 treated patients and 108 patients with
efficacy data, a total of 92 unique patients (37 females and 55
males) receiving a total of 12,453 infusions were included in
the HRQOL analysis sets (those with completed HRQOL as-
sessments). The age range was 3–69 years. Demographic and
Screening clinical characteristics of patients from each study
are summarized in Table 1.
Switch Studies
LQI Scores from Individual Switch Studies
In the EU and JP switch studies, there was a significant in-
crease (improvement) from Screening in LQI domain scores at
all time points (Table 2; Fig. 1a, b). In both studies, there was a
significant improvement from Screening in the mean domain
scores for Treatment Interference, Therapy Setting, and
Treatment Costs at Week 12 and Week 24, and for Therapy-
Related Problems at Week 12 (Table 2). Changes in the do-
mains of Treatment Interference and Therapy Setting were
mostly moderately meaningful at all time points, while those
in Therapy-Related Problems and Treatment Costs were min-
imally meaningful. In the JP switch study, changes in all do-
mains except Therapy-Related Problems (minimally-to-mod-
erately meaningful changes) were highly meaningful
(Table 2).
In the EU switch study, improvement in Therapy-Related
Problems continued toWeek 40, the final study visit (Fig. 1a).
In the JP switch study, as noted earlier, the last visit was in
Week 24. In the EU switch study, where patients were allowed
to switch from both IVIG or another SCIG to Hizentra®,
improvements in the LQI domain scores were largely driven
by patients switching from IVIG to SCIG (n = 27), rather than
patients switching from other SCIG preparations to Hizentra®
SCIG (n = 19), for whom changes were not statistically sig-
nificant (Fig. 2).
Changes from Screening in individual LQI item scores in
the EU and JP switch studies are shown in Table S1. There
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were significant improvements for the majority of LQI items
atWeek 12 andWeek 24 in both the EU and JP switch studies.
LQI Scores from Pooled Analysis of Switch Studies
Analysis of the pooled data from the EU and JP switch studies
showed significant improvements in all LQI domain scores
(Treatment Interference, Therapy-Related Problems, Therapy
Setting, and Treatment Costs) from Screening. Most improve-
ment occurred between Screening and Week 12, which was
sustained at subsequent time points (Weeks 24 and 40, Fig. 3).
Changes from Screening to Week 40 in individual LQI
item (question) scores from pooled data analysis of the EU
and JP switch studies were consistent, with statistically signif-
icant improvements in all but four items (Fig. 4).
SF-36v2 Scores from Individual Switch Studies
In the EU switch study, there were significant increases in mean
SF-36v2 domain scores for Physical Function and General
Health from Screening to Week 12 and to Week 24 (Table 3).
These improvements were observed also at Week 24 (Table 3).
Improvement was also observed for the Role Emotional do-
main at Weeks 24 and 40; these were minimally-to-
moderately meaningful (Table 3). Other domains of the SF-
36v2 were not associated with significant or meaningful chang-
es. SF-36v2 was not assessed in the US or JP switch studies.
In the EU switch study, previous treatment (IVIG vs SCIG)
had little impact on change in SF-36v2 scores, although atWeek
12, there was a significant improvement in Physical Functioning
and Global Health domains in patients switching from IVIG that
was not observed in patients switching from SCIG (Fig. 5).
Table 1 Patient characteristics at Screening (populations used for HRQOL evaluation)
EU switch EU maintenance JP switch JP maintenancea US maintenance
Total number of patients 51 40 24 23 17
Gender, n (%)
Female 16 (31.4) 12 (30) 9 (37.4) 9 (39.1) 12 (70.6)
Male 35 (68.6) 28 (70) 15 (62.5) 14 (60.9) 5 (29.4)
Age (years)
Mean (SD) 22.6 (15.86) 21.6 (15.31) 20.5 (13.5) 20.8 (13.68) 45.1 (16.03)
Median (range) 18 (3, 60) 16.0 (4, 52) 17.5 (3, 58) 17.0 (4, 58) 44 (11, 69)
Body mass index (kg/m2)
Mean (SD) 20.64 (4.66) 20.54 (4.67) 18.8 (3.74) 18.9 (3.19) 27.7 (6.24)
Median (range) 20.2 (12.3, 31.8) 20.55 (13.9, 31.4) 18.2 (15, 33) 18.4 (15, 30) 28 (17.6, 42.7)
Primary disease, n (%)
CVID 30 (58.8) 23 (57.5) 10 (42.0) 10 (43.5) 17 (100)
XLA 20 (39.2) 16 (40.0) 12 (50.0) 11 (47.8) –
ARAG 1 (2.0) 1 (2.5) 1 (4.2) 1 (4.3) –
LQI domain score at Screening, mean (SD)
Treatment Interference 69.25 ± 21.77 83.76 (16.00) 52.78 (22.22) 73.91 (16.30) 83.18 ± 14.15
Therapy-Related Problems 72.64 ± 20.16 80.56 (14.97) 56.50 (21.35) 63.59 (17.37) 77.78 ± 16.17
Therapy Setting 72.96 ± 24.73 89.60 (15.46) 56.89 (22.24) 78.99 (19.67) 87.96 ± 13.10
Treatment Costs 58.33 ± 30.53 66.67 (22.21) 46.33 (27.12) 71.74 (18.93) 84.26 ± 18.05
SF-36v2 domain score at Screening, mean (SD)
Physical Functioning 86.97 ± 17.23 92.95 ± 7.51 – – 78.24 ± 23.91
Role Physical 78.60 ± 22.75 84.66 ± 22.55 – – 81.99 ± 21.30
Bodily Pain 74.97 ± 23.04 82.84 ± 20.93 – – 73.53 ± 20.81
General Health 42.82 ± 17.37 50.00 ± 19.52 – – 50.00 ± 20.77
Vitality 58.90 ± 21.37 65.06 ± 13.59 – – 56.25 ± 16.68
Social Functioning 84.85 ± 18.42 89.20 ± 12.96 – – 78.68 ± 22.86
Role Emotional 84.60 ± 18.30 91.29 ± 17.91 – – 85.29 ± 24.57
Mental Health 76.21 ± 11.39 80.00 ± 11.13 – – 70.29 ± 15.46
ARAG autosomal recessive agammaglobulinemia, AT all-treated, CVID common variable immune deficiency, FAS full analysis set, HRQOL health-
related quality of life, ITT intention-to-treat, LQI Life Quality Index, n number of patients, n.a. data not available, SD standard deviation, SF-36v2 Short
Form 36 version 2, XLA X-linked agammaglobulinemia
a Study includes data from two studies: JP follow-up (NCT01458171) and extension (NCT01461018) studies
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Maintenance Studies
LQI Scores from Individual Maintenance Studies
LQI scores were sustained in the maintenance (follow-up/ex-
tension) studies. Mean LQI domain scores in the EU, JP, and
US maintenance studies were stable and in one case improved
(Fig. 1), suggesting that patient-reported IgG treatment-
specific HRQOL was sustained over a long period of time
(up to 208 weeks in the combined EU switch and maintenance
studies).
Table 2 LQI domain scores in EU and JP switch studies
LQI domain
by visit
EU switch JP switch
N Change from
Screening, mean (SD)
p values
of changea
Effect size
(meaningfulness
of change)
N Change from
Screening, mean (SD)
p values
of changea
Effect size
(meaningfulness
of change)
Treatment Interference (0–100)
Week 12 47 9.91 (20.49) 0.0012 0.48 (minimally) 24 26.18 (19.42) < 0.0001 1.35 (highly)
Week 24 44 13.51 (20.27) < 0.0001 0.66 (moderately) 24 20.04 (19.42) < 0.0001 1.03 (highly)
Therapy-Related Problems (0–100)
Week 12 47 4.56 (16.89) 0.0662 0.27 (minimally) 24 9.86 (19.91) 0.0193 0.50 (moderately)
Week 24 44 7.50 (16.72) 0.0035 0.45 (minimally) 24 7.66 (19.91) 0.0660 0.39 (minimally)
Therapy Setting (0–100)
Week 12 47 13.81 (23.27) < 0.0001 0.59 (moderately) 24 26.82 (23.40) < 0.0001 1.15 (highly)
Week 24 44 16.61 (22.99) < 0.0001 0.72 (moderately) 24 21.26 (23.40) < 0.0001 0.91 (highly)
Treatment Costs (0–100)
Week 12 47 11.24 (29.96) 0.0112 0.37 (minimally) 24 29.43 (23.64) < 0.0001 1.24 (highly)
Week 24 44 12.51 (29.59) 0.0058 0.42 (minimally) 24 25.61 (23.64) < 0.0001 0.92 (highly)
LQI Life Quality Index
a p < 0.05
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LQI Scores from Pooled Analysis of Maintenance Studies
Analysis of pooled data from the maintenance studies also
showed that LQI scores on all four domains were sustained
(i.e., no statistically significant longitudinal change) at the
follow-up time points; further, there was significant improve-
ment in Therapy-Related Problems at Month 30 and
Treatment Costs at Months 6 and 18 (Table S2). Changes
from Screening to Month 24 in individual LQI items from
the pooled data analysis of the EU and US maintenance stud-
ies were positive on 11/15 items, and one even showed a
statistically significant improvement (Not Painful; Fig. 6).
SF-36v2 Scores from Individual Maintenance Studies
Overall, SF-36v2 domain scores were maintained from
Screening toMonth 24 in the EU andUSmaintenance studies;
further, there was an improvement in Physical Functioning at
Month 6 (+6.53, p = 0.03) and Month 12 (+6.04, p = 0.04) in
the US maintenance study (Table S3).
SF-36v2 Scores from Pooled Analysis of Maintenance Studies
The pooled data analysis of the EU and US maintenance stud-
ies showed maintenance of scores on all SF-36v2 domains
from Screening to Month 24 of follow-up (Fig. 7). Similar
results were observed for changes in individual SF-36v2 ques-
tions at Month 24 from the pooled data analysis of these stud-
ies (Fig. 8).
Discussion
This analysis of six Phase 3 clinical studies showed meaning-
ful improvement for several relevant aspects of IgG treatment-
specific HRQOL (as measured by the LQI) and health status
(as measured by SF-36v2) in patients with PIDD upon
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switching from IVIG or another SCIG to Hizentra®, which
was maintained for up to 3 years. Specifically, in two studies
(EU and JP) involving a switch from IVIG to SCIG, LQI and
SF-36v2 domain scores improved significantly from initial
Screening, as early as Week 12 with sustained improvement
through Week 24. In the EU switch study, where patients had
an option to switch from either IVIG or another SCIG to
Hizentra®, these improvements were almost exclusively
Table 3 SF-36v2 domain scores
in the EU switch study SF-36v2 domain by visit N Change from
Screening, mean (SD)
p values of changea Effect size
(meaningfulness of change)
Physical Functioning
Week 12 28 4.66 (8.52) 0.0049 0.55 (moderately)
Week 24 25 3.56 (8.40) 0.0372 0.42 (minimally)
Role Physical
Week 12 28 1.53 (17.51) 0.6456 0.087 (not)
Week 24 25 3.71 (17.25) 0.2852 0.22 (minimally)
Bodily Pain
Week 12 28 2.50 (20.15) 0.5133 0.12 (not)
Week 24 25 6.38 (19.83) 0.1119 0.32 (minimally)
General Health
Week 12 28 7.20 (17.51) 0.0326 0.41 (minimally)
Week 24 25 7.74 (17.23) 0.0277 0.45 (minimally)
Vitality
Week 12 28 4.15 (12.73) 0.0888 0.33 (not)
Week 24 25 − 0.05 (12.55) 0.9854 − 0.004 (not)
Social Functioning
Week 12 28 − 2.43 (13.57) 0.3463 − 0.18 (not)
Week 24 25 1.23 (13.37) 0.6479 0.092 (not)
Role Emotional
Week 12 28 1.05 (13.31) 0.6777 0.45 (minimally)
Week 24 25 5.96 (13.11) 0.0259 0.47 (minimally)
Mental Health
Week 12 28 0.32 (12.53) 0.8925 0.026 (not)
Week 24 25 1.25 (12.32) 0.6146 0.11 (not)
SF-36v2 Short Form 36 version 2
a p < 0.05
Fig. 4 Change from Screening to Week 40 in individual LQI question
scores from the pooled data analysis of the EU and JP switch studies. Data
are expressed asmean (95%CI). CI confidence interval, EUEuropean, JP
Japanese, LCI lower confidence interval, LQI Life Quality Index, UCI
upper confidence interval
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driven by patients switching from IVIG to SCIG. In fact, there
were no statistically significant changes observed in patients
who switched from another SCIG to Hizentra®.
These results on improvement following a switch from
IVIG to SCIG are consistent with past studies that have also
demonstrated an improvement in health status and IgG-
specific HRQOL perceptions, as measured by SF-36 and
LQI questionnaires [20, 21, 33, 34]. In one study, significant
improvements were seen from baseline to month 10 in the SF-
36 domains of Vitality, Mental Health, and Social Functioning
in patients switching from IVIG to SCIG [20]. Improvements
in other SF-36 domains, including Role Physical, Bodily Pain,
Role Emotional, Health Transition, and General Health have
also been shown following a switch from IVIG to SCIG [21,
33]. Furthermore, significant improvements in both the LQI
summary score and individual LQI domains have also been
reported [20, 21, 33, 34]. In our switch studies, the domains
most favorably impacted were Therapy Setting and Treatment
Interference, and to a smaller extent, Therapy-Related
Problems, for the LQI questionnaire, and Physical Function,
General Health, and to a lesser extent, Role Emotional for the
SF-36v2 questionnaire. Most improvements on the above do-
mains were at or near magnitudes of what is considered at
least moderately meaningful change.
Further, while our findings regarding an improvement in
outcomes (SF-36v2, LQI) following an IVIG to SCIG switch
are consistent with past literature, to our knowledge, ours is
the longest follow-up of patients with PIDD who were
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scores from the pooled data analysis of the EU and US maintenance
studies. Data are expressed as mean (95% CI). CI confidence interval,
EU European, LCI lower confidence interval, LQI Life Quality Index,
UCI upper confidence interval
J Clin Immunol
maintained on SCIG treatment. Generally, following improve-
ment, there were no significant changes in these HRQOL
measures during the long-term maintenance studies
(conducted in EU, JP, and the US), suggesting that improve-
ments in IgG treatment-specific HRQOL perceptions and pa-
tient health status were maintained with long-term Hizentra®
Fig. 8 Change from Screening to Month 24 in individual SF-36v2
questions from the pooled data analysis of the EU and US maintenance
studies. Data are expressed as mean (95%CI). CI confidence interval, EU
European, LCI lower confidence interval, SF-36v2 Short Form 36
version 2, UCI upper confidence interval, US United States
Fig. 7 SF-36v2 domain scores from the pooled analysis of the EU and US maintenance studies. Data are expressed as mean (95% CI). *p < 0.05 vs
screening visit. CI confidence interval, EU European, SF-36v2 Short Form 36 version 2, US United States
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treatment (up to 208 weeks). Overall, our results are consistent
with a recent study that, in addition to demonstrating improve-
ment with an IVIG to SCIG switch, showed the benefit to be
maintained for up to 90 weeks [35].
Findings from our study highlight the multi-dimensional na-
ture of PIDD and its treatment. Evidence from the switch studies
demonstrated improvements in domains that reflect patient con-
venience, comfort, independence, treatment schedule flexibility,
pleasantness of treatment setting, and less disruption of daily
activities. These improvements are perhaps not surprising, given
a change from treatment typically administered intravenously in
a healthcare setting to home-based SCIG treatment which offers
increased patient flexibility [29]. In addition, although our find-
ings on Treatment Costs based on LQI are not meaningful as a
result of the artificial nature of a clinical trial setting, evidence
from real-world studies has demonstrated cost savings when
switching from IVIG to SCIG for treatment of PIDD [36–38].
The evidence also showed improvements in patient-
reported Physical Function and General Health following the
IVIG to SCIG switch, consistent with previously reported
improvements in Vitality [20, 21]. Improvements in these do-
mains may reflect the impact of stable serum IgG levels char-
acteristic of SCIG treatment, including both higher IgG trough
concentrations and reduced peak-to-trough variation achieved
through more frequent SCIG treatments, i.e., less wear-off
manifested in reduced fatigue [23, 33, 39]. In addition, pa-
tients receiving treatment at home may have a reduced expo-
sure to nosocomial infections, further increasing the likeli-
hood of a perceived improvement in general health. Our re-
sults therefore support the idea that maintaining stable serum
IgG levels translates into improvements in physical function,
and moreover, overall general health.
Consistent with the multidimensional nature of PIDD and its
treatment, we observed no improvement in some domains of
patient-reported outcomes. The Mental Health summary score
as measured by SF-36v2 did not change after switching to
SCIG. Similarly, the Treatment Costs domain on the LQI was
generally not impacted. At the item level, there was lack of
improvement with an IVIG to SCIG switch on the LQI items
of ImprovedHealth, Treatment BeingWorthwhile, andDoes Not
Make Anxious or Nervous. Findings such as these, especially on
the overarching LQI item Improved Health, arguably serve as
reminders that PIDD is a chronic condition and may continue to
exact a toll in the long run, unaffected by a switch in treatment
modality. Further, domains such as emotional status are less
likely to be impacted given that they are likely confounded by
additional extraneous influences (not explored in these studies),
consistent with the Wilson Cleary classification of health out-
comes into those that are more immediately impacted by inter-
ventions (in this case, a switch from IVIG to SCIG) and those
that are likely to be confounded by other factors [40].
Accordingly, it is also not surprising that while a switch in mo-
dality from IVIG to SCIG was manifested in an immediate
improvement in domains that measured convenience aspects,
but not so on domains and items relating to perceptions of in-
tervention cost, as all study medication costs were covered by
the study sponsor. However, in clinical practice, these factors are
likely to impact patients variously, based on their healthcare
system dynamics. Absence of improvement on the item Does
Not Make Them Anxious or Nervous following a change to
SCIG in both the switch and long-term maintenance phases
may highlight the need for physicians to carefully consider those
who may not be good candidates for self-infusion by encourag-
ing shared decision making in consultation with the patient.
Finally, our findings on fatigue were somewhat mixed. In
past research, patients with primary antibody deficiency have
been shown to have higher fatigue levels (25.9%; 95% CI
23.7–28.3) compared with the general population (6–7.5%)
[41, 42] and to patients with PIDD who had a condition dif-
ferent from primary antibody deficiency (6.3%; 95% CI 4.9–
8.2) [43]. Moreover, patients with common variable immune
deficiency, which constituted the large majority of the popu-
lation in our studies, have been shown to have the highest
fatigue levels of all patients with PAD [43]. Fatigue levels
have also been shown to be similar regardless whether patients
received IVIG or SCIG [43]. In our studies, we assessed
Vitality, i.e., the obverse of fatigue, as part of the SF-36v2
and found scores to be uniformly lower (worse) than on other
domains, consistent with past work. We also found only mar-
ginal improvements in Vitality in the switch studies, which
were nevertheless maintained in the longer term, again poten-
tially reflective of the chronic nature of disease and frequency
of treatment.
Strengths and Limitations of This Analysis
This is the first analysis of pooled data from two switch and
four maintenance (follow-up/extension) studies evaluating pa-
tient-reported HRQOL outcomes both after a switch from
IVIG to SCIG treatment and during long-term SCIG mainte-
nance treatment, in patients with PIDD. Further, this study is
unique in reporting not just outcomes by domain, but also
improvements on each of the 15 LQI items and 36 SF-36v2
items. Recently, there has been debate over the utility of ag-
gregation scores from ordinal scales to arrive at summary
measures, as is often reported [44]. Indeed, the developers of
the SF-36 questionnaire have stated that it is not appropriate to
combine all domains to produce one overall score [44]. While
advanced psychometric evaluation of the measurement and
aggregation properties of the items based on modern item
response theory [45, 46] was outside the scope of this paper,
at least by presenting outcomes for individual items, in addi-
tion to domains, we hope this paper provides a more transpar-
ent profile of the impact of IgG therapy on HRQOL.
Limitations include the different time points of data collec-
tion across studies, allowing for comparison and pooling of
J Clin Immunol
data at selected time points only, and the fact that completed
questionnaires were not returned by all patients at each time
point. Furthermore, an active comparator cohort or placebo
cohort were not included into design of these studies. Finally,
many of the factors that may have confounded HRQOL, in-
cluding complexities with self-administration (such as vial
sizes and/or numbers of times the vials needed to be switched,
and need to replace the pump) as well as the influence of any
improvements in serum trough IgG levelswere not specifically
analyzed for this report.
Conclusions
The results from the switch (pivotal) Hizentra® studies where
HRQOL was assessed showed that switching patients from
IVIG to SCIG improves patient self-reported health status
and IgG-specific HRQOL perception. The maintenance
(extension) studies generally showed no deterioration of the
improved health status achievedwhen switching from IVIG to
SCIG treatment with Hizentra® over a long follow-up period.
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